Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Super-Detailed brain scans could reveal early signs of Alzheimer's, Parkinson's, and ALS

NCT ID NCT07509125

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses a new ultra-high-resolution PET scanner to take detailed pictures of the brain and spinal cord in 300 healthy volunteers and people with conditions like Alzheimer's, Parkinson's, ALS, and psychotic disorders. The goal is to understand how small brain regions change with age and disease, which could help doctors diagnose these conditions earlier. Participants will have brain scans and complete memory, mood, and movement tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * WP1: Healthy controls * Age between 18 and 90 years old (15 aged 18-50 years and 25 aged 50 90 years); * Subject is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs and clinical laboratory tests; * No history or evidence of current major neurological, internal or psychiatric disorder, based on the medical assessment as described hereabove and neuropsychological assessment; * No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline; * In subjects \< 60 years of age, a normal structural MRI scan as assessed by expert radiologist. * In subjects \>= 60 years of age white matter hyperintensities corresponding to a WML (white matter lesion) score \<= 2 (of 3) on the Age-Related White Matter changes scale are acceptable; * When older than 50 years of age, the volunteer is willing to undergo a p- tau217 blood sample. * WP2: Dementia * Patient has a clinical diagnosis of biomarker-proven prodromal AD * WP3: ALS spectrum * Subject must meet El Escorial Criteria (30) and Awaji-Shima criteria (31) for at least possible ALS; * WP4: Movement disorders * (all): Patient (or legal representative, when applicable) is able to understand the patient information form and give written informed consent. * Parkinson´s disease (PD): * Patient has clinically established PD based on the Movement Disorder Society (MDS) diagnostic criteria (32); * Patient has an abnormal 18F-PE2I PET; * No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline. * Multiple system atrophy (MSA) * Patient has clinically established or clinically probable MSA-P based on the * Movement Disorder Society (MDS) diagnostic criteria (33); * Patient has an abnormal 18F-PE2I PET. * Progressive supranuclear palsy (PSP) * Patient has an abnormal 18F-PE2I PET; * Patient has clinically established probable PSP according to the latest MDS criteria * Dementia with Lewy bodies (DLB) * Patient has probable DLB by consensus criteria (cognitive impairment MoCA \< 26 + visual hallucinations and/or fluctuating alertness); * Patient has an abnormal 18F-PE2I PET. * Idiopathic REM sleep behavior disorder (iRBD) * Patient has Polysomnography-confirmed iRBD; * No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline; * No clinical evidence of parkinsonism at baseline. * WP5: Psychosis * DSM 5 criteria for a non-affective schizophrenia spectrum psychotic disorder; * Age between 18 and 55 years old for adult-onset psychosis, onset of psychosis (and age) above 60 years old for very late onset psychosis. Exclusion Criteria: * Subject has a history of any major (other) internal, psychiatric or neurological disease that may interfere with the investigations (especially liver and kidney disease, uncontrolled diabetes, cancer, severe depression, stroke, severe TBI); * Subject is currently a user (including recreational use) of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse; * Subject chronically uses medication that has central nervous system effects (e.g. strong painkillers such as opioids, neuroleptics,..; ) (other than prescribed for the illness in case of patients); * Subject has had exposure to ionizing radiation (\> 1 mSv) in other research studies within the last 12 months; * Subject has a contra-indication for MRI scanning; * Subject suffers from claustrophobia or cannot tolerate confinement during PET-MRI scanning procedures; subject cannot lie still for (at least) 60 minutes inside the scanner; * (For subjects with arterial sampling): The subject is hypersensitive to lidocaine (used for local anaesthesia during the placement of the arterial catheter), has an abnormal Allen test (a test to check blood flow in the arteries of the forearm) or is on anti-coagulant therapy; * Subject (or his/her legal representative) does not understand the study procedures; * Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator; * Subject is potentially pregnant (hCG test can be done if doubt exists).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult onset psychotic disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UZ Leuven

    RECRUITING

    Leuven, Vlaams-Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.